MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by State Street Corp

State Street Corp boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 5.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,269,135 shares of the company’s stock after purchasing an additional 111,066 shares during the period. State Street Corp’s holdings in MaxCyte were worth $8,827,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in shares of MaxCyte by 24.4% during the second quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company’s stock valued at $1,659,000 after buying an additional 83,025 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after acquiring an additional 5,927 shares during the period. Rhumbline Advisers grew its stake in MaxCyte by 15.3% during the 2nd quarter. Rhumbline Advisers now owns 157,616 shares of the company’s stock valued at $618,000 after purchasing an additional 20,864 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of MaxCyte by 10.7% in the second quarter. American Century Companies Inc. now owns 144,110 shares of the company’s stock valued at $565,000 after purchasing an additional 13,904 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of MaxCyte by 13.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after purchasing an additional 121,090 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

Insiders Place Their Bets

In other news, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now owns 269,118 shares of the company’s stock, valued at $998,427.78. This trade represents a 7.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.00% of the stock is owned by insiders.

MaxCyte Stock Down 1.0 %

MaxCyte stock opened at $4.07 on Friday. The stock has a 50-day moving average price of $3.76 and a 200 day moving average price of $4.04. The company has a market capitalization of $430.16 million, a price-to-earnings ratio of -11.97 and a beta of 1.37. MaxCyte, Inc. has a 52 week low of $3.16 and a 52 week high of $5.55.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period in the previous year, the business posted ($0.11) EPS. Research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.